Sentences with phrase «survival by chemotherapy»

Not exact matches

Prof Kirby said improving survival rates on patients receiving chemotherapy, which can extend life expectancies by up to three years, meant it was a «big mistake to let him out on the premise that he would be dead within three months».

«In an earlier phase I clinical study, our group has shown that increasing the dose of radiation delivered daily with high precision and using image guidance may offset the need for chemotherapy in improving survival, and it may also improve quality of life measures by reducing treatment periods in half.

New research posted online by the Nature journal Leukemia suggests blocking part of a DNA repair complex that helps some types of leukemia resist treatment can increase the effectiveness of chemotherapy and enhance survival.

Of the dogs stricken with osteosarcoma, 35 had the cancer in a leg which was subsequently amputated, followed by chemotherapy, which is the standard - of - care treatment; the dogs with elevated total cholesterol had a median survival time of 455 days, more than 200 days greater than the median survival time for dogs with normal cholesterol.

Among this group, chemotherapy is known to increase survival by up to 20 percent and is routinely recommended following surgery.

«We hope that our test will significantly improve the odds of survival of breast cancer patients by allowing doctors to identify the most effective but least toxic form of chemotherapy for each individual patient before the treatment begins.»

The interim analysis found a median progression - free survival rate of 9.7 months with consolidative radiation therapy followed by chemotherapy, versus 3.5 months for maintenance chemotherapy alone (p = 0.01; Hazard Ratio (HR) = 0.304, 95 % CI 0.113 - 0.815).

A drug used to treat men with late - stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University (OHSU).

The addition of necitumumab to gemcitabine and cisplatin chemotherapy improved overall survival and progression free survival by 21 % and 16 %, respectively, as compared to chemotherapy alone in patients whose tumours expressed the EGFR protein.

The investigators found that pembrolizumab significantly improved the primary endpoint of progression - free survival by approximately four months compared to chemotherapy (10.3 months versus 6.0 months, hazard ratio [HR] 0.50).

In mice with pancreatic cancer, three days of fasudil treatment prior to standard chemotherapy increased survival time by 47 per cent.

The period of time before ovarian cancer recurred (called progression - free survival) improved by nearly 3.5 months with the additional drug (13.8 months compared with 10.4 months for the woman on chemotherapy alone).

However, adjuvant chemotherapy did not improve survival or disease - free survival, but we noted that the curves by adjuvant treatment did diverge progressively starting from year four for overall survival and from year two for disease - free survival.

Based on recent information on the mechanisms of chemotherapy, a team of researchers of the McGill University Health Centre (MUHC) developed a new clinical approach to increase the efficiency of treatment in glioblastomas that increased the median survival to 22 months — bringing much needed hope to those affected by this aggressive disease.

They analyzed the association between body mass index (weight divided by height) and progression - free survival (PFS) and overall survival (OS) in six independent cohorts of patients treated with targeted therapy, immunotherapy or chemotherapy in pivotal trials that led to FDA approval of these drugs.

A major clinical trial randomizing patients to either initial surgery followed by chemotherapy, or chemotherapy then surgery, revealed no significant difference in overall survival between the groups.

The study, led by Deborah Armstrong at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland, builds upon evidence from eight other clinical trials showing an overall survival benefit of approximately one year for women treated with IP chemotherapy after «optimal debulking» — surgery to remove most, if not all, of the cancer in the abdomen.

Women with Stage III ovarian cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Medicine.

Surgery, radiation and chemotherapy do prolong survival by several months, but targeted therapies, which have been effective with other forms of cancer, have not lengthened survival in patients fighting glioblastoma.

The addition of metronomic chemotherapy to dual HER2 blockade increased progression - free survival (PFS) by 7 months compared with HER2 blockade alone in older and frail patients with HER2 - positive metastatic breast cancer, according to a new study.

Our researchers show how more frequent, higher doses of chemotherapy improves survival in some young patients by two - thirds.

Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy should help boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy.

For patients with stage II or stage III colon cancer, the difference in long - term survival for leaner patients compared to those with a body mass index (BMI) of 35 or greater — which physicians refer to as «very obese» — was comparable to the difference between those who had surgery followed by chemotherapy and those who had only surgery.

The rationale is that chemotherapy and immunotherapy can induce autophagy in tumor cells, which in turn is used by tumor cells as a survival mechanism to resist pharmaceutical invention.

In other words, the goal of the study was to look at how significant chemotherapy's role was in successful treatment outcomes (defined by oncologists as five - year survival).

Surgical removal does not significantly add to the survival time achieved by chemotherapy.

Only a few studies have evaluated treatment of this disease, and the most successful treatment (to date) that we know of involves a relatively invasive surgery to remove the sac around the heart followed by a course of chemotherapy, leading to survival times averaging about 6 months.

The prognosis for cats by surgery alone is poor while cats who have received surgery plus radiation or chemotherapy improve with a higher survival rate.